NEW YORK--(BUSINESS WIRE)--Acuamark Diagnostics, Inc., a biotechnology company that focuses on developing accurate and cost-effective blood-based screening tests for the early detection of cancer, today announced the addition of Mr. Haywood D. Cochrane to its Board of Directors. Mr. Cochrane will transition from his current position as member of Acuamark Diagnostics’ Advisory Board.
Mr. Cochrane is a seasoned industry executive with over 30 years of healthcare, laboratory and diagnostics industry experience in executive and senior management positions. Currently, Mr. Cochrane serves as a Director of Corium, Inc., and is Vice Chair of the Board of Trustees at the University Of North Carolina At Chapel Hill.
Mr. Cochrane states: “I am truly delighted to join Bernard, Michael and Francis and their outstanding Board as we continue to build on this great technology to commercialize a unique and cost-effective diagnostic tool in the large and critical area of early-stage cancer detection.”
Previously, Mr. Cochrane served as Chief Executive Officer of CHD Meridian, Inc., which became the largest provider of integrated, on-site corporate healthcare management solutions in the United States (now part of Walgreens). Mr. Cochrane also served as the President and CEO of Allied Clinical Laboratories (acquired by NHL). Also, he was EVP, CFO and Treasurer at Laboratory Corporation of America Holdings (LabCorp); Earlier, he was COO at Biomedical Reference Labs and COO at Roche Biomedical Labs. Mr. Cochrane has had a variety of public and private company Board roles, and - amongst others - served as Director at American Esoteric Labs, Ameripath and Unilab Corporation.
Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. comments: "After working with Haywood on our Advisory Board, we are very excited to welcome him to our Board of Directors. He brings a wealth of strategic and transactional knowledge in the healthcare management and diagnostics industry.”
Mr. Michael Gargano, Chairman of the Board of Acuamark Diagnostics, further adds: “We are pleased that Haywood has chosen to join Acuamark Diagnostics’ Board of Directors. Haywood is a respected pioneer and leader in the diagnostics industry.”
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing screening tests for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.